270 related articles for article (PubMed ID: 10051050)
1. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
van Mourik ID; Thomson M; Kelly DA
Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
4. Neoral use in the cardiac transplant recipient.
Valantine H
Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748
[TBL] [Abstract][Full Text] [Related]
5. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
6. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.
Graziadei IW; Wiesner RH; Marotta PJ; Porayko MK; Dahlke LJ; Wilson SM; Steers JL; Krom RA
Transplantation; 1997 Sep; 64(5):726-31. PubMed ID: 9311710
[TBL] [Abstract][Full Text] [Related]
7. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
Akhlaghi F; Gonzalez L; Trull AK
J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
[TBL] [Abstract][Full Text] [Related]
8. Experience with neoral versus sandimmune in primary liver transplant recipients.
Pinson CW; Chapman WC; Wright JK; Hunter EB; Awad JA; Raiford DS; Payne JL; Geevarghese S; Blair TK; Van Buren DH
Transpl Int; 1998; 11 Suppl 1():S278-83. PubMed ID: 9664997
[TBL] [Abstract][Full Text] [Related]
9. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.
Mendez R; Abboud H; Burdick J; Copley B; Freeman R; Batiuk TD; Cooney GF; Barbeito R
Clin Ther; 1999 Jan; 21(1):160-71. PubMed ID: 10090433
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors.
Akhlaghi F; Keogh AM; McLachlan AJ; Kaan A
J Heart Lung Transplant; 2001 Apr; 20(4):431-8. PubMed ID: 11295581
[TBL] [Abstract][Full Text] [Related]
11. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption.
Trompeter R; Fitzpatrick M; Hutchinson C; Johnston A
Pediatr Transplant; 2003 Aug; 7(4):282-8. PubMed ID: 12890006
[TBL] [Abstract][Full Text] [Related]
14. NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation.
Alvarez F; Atkison PR; Grant DR; Guilbault N; Jones AB; Kim PS; Kneteman NM; Laurin L; Martin SR; Murphy GF; Paradis K; Shapiro J; Smith LJ; Superina RA
Transplantation; 2000 Jan; 69(1):87-92. PubMed ID: 10653385
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
Keown P; Niese D
Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
[TBL] [Abstract][Full Text] [Related]
16. Neoral in de novo liver transplantation: adequate immunosuppression without intravenous cyclosporine.
Levy GA; Rasmussen A; Mayer AD; Jamieson NV; Neuhaus P
Liver Transpl Surg; 1997 Nov; 3(6):571-7. PubMed ID: 9404955
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the pharmacokinetics of cyclosporine in patients following long-term administration after a kidney transplant: comparison of Neoral and Sandimmune.
Takahara S; Ichimaru N; Kojima Y; Namba Y; Toki K; Shi Y; Yoshimura K; Matsumiya K; Nonomura N; Okuyama A
Transplant Proc; 2004 Mar; 36(2 Suppl):456S-460S. PubMed ID: 15041387
[TBL] [Abstract][Full Text] [Related]
18. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
[TBL] [Abstract][Full Text] [Related]
19. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral.
Pasha TM; Wiesner RH; Dahlke LM; Porayko MK; Krom RA
Liver Transpl Surg; 1998 Sep; 4(5):410-5. PubMed ID: 9724479
[TBL] [Abstract][Full Text] [Related]
20. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]